Circassia Invests $377 Million in Asthma Specialists
UK-based Circassia invests approximately $377 million on Aerocrine and Prosonix, two companies focused on asthma.
Circassia Pharmaceuticals, a company focused on immunotherapies for the treatment of allergies, announced on May 15, 2015 that it agreed to buy Aerocrine and Prosonix for £239 million, or approximately US$377 million, according to an article from Reuters. The two companies, which are focused on developing treatments for asthma, will receive separate payments of approximately US$219 million (Aerocrine) and approximately US$158 million (Prosonix).
"Aerocrine has products that they sell to allergy asthma specialists, the very customers we want to sell our allergy products to, so that's a really good strategic fit. Prosonix has near-term products that help us create an allergy-asthma specialist pharmaceutical company,” said Steve Harris, CEO of Circassia, in an interview with Reuters.
Sources:
ReutersAerocrineProsonix
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
